The effect of hepatic disease on the disposition of moricizine in humans

H. J. Pieniaszek, A. F. Davidson, C. M. McEntegart, C. Y. Quon, R. E. Sampliner, Michael Mayersohn

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The pharmacokinetics of moricizine and two of its metabolites, moricizine sulfoxide and phenothiazine-2-carbamic acid ethyl ester sulfoxide, were studied in healthy control subjects and in patients with chronic liver disease (cirrhosis). Moricizine disposition was significantly altered by hepatic cirrhosis. Compared to healthy subjects, the hepatic disease patients had an increased C(max) (59%), an increased t( 1/2 ) (141%), and a reduced plasma clearance (71%). Additionally, small but statistically significant increases were observed for t(max) and the fraction of moricizine not bound to plasma proteins in patients with hepatic disease. The elimination of both moricizine metabolites was also altered by hepatic dysfunction as indicated by significantly prolonged terminal half-lives. Furthermore, there was a reduction in the conversion of moricizine to moricizine sulfoxide. Both hepatic blood flow and hepatic metabolizing capacity were assessed in all subjects and patients by administration of indocyanine green and antipyrine, respectively. Indocyanine green and antipyrine plasma clearances were decreased by 38 and 51%, respectively, indicating that both functions were diminished by hepatic cirrhosis. We conclude that the moricizine dose required for arrhythmia patients with hepatic disease should be lower, and perhaps, the dosing frequency should be less than in patients with normal liver function.

Original languageEnglish (US)
Pages (from-to)243-252
Number of pages10
JournalBiopharmaceutics and Drug Disposition
Volume15
Issue number3
StatePublished - 1994

Fingerprint

Moricizine
Liver
Liver Cirrhosis
Antipyrine
sulfoxide
Indocyanine Green
Healthy Volunteers
Urethane
Liver Diseases
Cardiac Arrhythmias
Blood Proteins
Chronic Disease
Pharmacokinetics

Keywords

  • antipyrine
  • hepatic cirrhosis
  • indocyanine green
  • moricizine
  • pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pieniaszek, H. J., Davidson, A. F., McEntegart, C. M., Quon, C. Y., Sampliner, R. E., & Mayersohn, M. (1994). The effect of hepatic disease on the disposition of moricizine in humans. Biopharmaceutics and Drug Disposition, 15(3), 243-252.

The effect of hepatic disease on the disposition of moricizine in humans. / Pieniaszek, H. J.; Davidson, A. F.; McEntegart, C. M.; Quon, C. Y.; Sampliner, R. E.; Mayersohn, Michael.

In: Biopharmaceutics and Drug Disposition, Vol. 15, No. 3, 1994, p. 243-252.

Research output: Contribution to journalArticle

Pieniaszek, HJ, Davidson, AF, McEntegart, CM, Quon, CY, Sampliner, RE & Mayersohn, M 1994, 'The effect of hepatic disease on the disposition of moricizine in humans', Biopharmaceutics and Drug Disposition, vol. 15, no. 3, pp. 243-252.
Pieniaszek HJ, Davidson AF, McEntegart CM, Quon CY, Sampliner RE, Mayersohn M. The effect of hepatic disease on the disposition of moricizine in humans. Biopharmaceutics and Drug Disposition. 1994;15(3):243-252.
Pieniaszek, H. J. ; Davidson, A. F. ; McEntegart, C. M. ; Quon, C. Y. ; Sampliner, R. E. ; Mayersohn, Michael. / The effect of hepatic disease on the disposition of moricizine in humans. In: Biopharmaceutics and Drug Disposition. 1994 ; Vol. 15, No. 3. pp. 243-252.
@article{dda929da356449eb8e41f0a6ec68da80,
title = "The effect of hepatic disease on the disposition of moricizine in humans",
abstract = "The pharmacokinetics of moricizine and two of its metabolites, moricizine sulfoxide and phenothiazine-2-carbamic acid ethyl ester sulfoxide, were studied in healthy control subjects and in patients with chronic liver disease (cirrhosis). Moricizine disposition was significantly altered by hepatic cirrhosis. Compared to healthy subjects, the hepatic disease patients had an increased C(max) (59{\%}), an increased t( 1/2 ) (141{\%}), and a reduced plasma clearance (71{\%}). Additionally, small but statistically significant increases were observed for t(max) and the fraction of moricizine not bound to plasma proteins in patients with hepatic disease. The elimination of both moricizine metabolites was also altered by hepatic dysfunction as indicated by significantly prolonged terminal half-lives. Furthermore, there was a reduction in the conversion of moricizine to moricizine sulfoxide. Both hepatic blood flow and hepatic metabolizing capacity were assessed in all subjects and patients by administration of indocyanine green and antipyrine, respectively. Indocyanine green and antipyrine plasma clearances were decreased by 38 and 51{\%}, respectively, indicating that both functions were diminished by hepatic cirrhosis. We conclude that the moricizine dose required for arrhythmia patients with hepatic disease should be lower, and perhaps, the dosing frequency should be less than in patients with normal liver function.",
keywords = "antipyrine, hepatic cirrhosis, indocyanine green, moricizine, pharmacokinetics",
author = "Pieniaszek, {H. J.} and Davidson, {A. F.} and McEntegart, {C. M.} and Quon, {C. Y.} and Sampliner, {R. E.} and Michael Mayersohn",
year = "1994",
language = "English (US)",
volume = "15",
pages = "243--252",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - The effect of hepatic disease on the disposition of moricizine in humans

AU - Pieniaszek, H. J.

AU - Davidson, A. F.

AU - McEntegart, C. M.

AU - Quon, C. Y.

AU - Sampliner, R. E.

AU - Mayersohn, Michael

PY - 1994

Y1 - 1994

N2 - The pharmacokinetics of moricizine and two of its metabolites, moricizine sulfoxide and phenothiazine-2-carbamic acid ethyl ester sulfoxide, were studied in healthy control subjects and in patients with chronic liver disease (cirrhosis). Moricizine disposition was significantly altered by hepatic cirrhosis. Compared to healthy subjects, the hepatic disease patients had an increased C(max) (59%), an increased t( 1/2 ) (141%), and a reduced plasma clearance (71%). Additionally, small but statistically significant increases were observed for t(max) and the fraction of moricizine not bound to plasma proteins in patients with hepatic disease. The elimination of both moricizine metabolites was also altered by hepatic dysfunction as indicated by significantly prolonged terminal half-lives. Furthermore, there was a reduction in the conversion of moricizine to moricizine sulfoxide. Both hepatic blood flow and hepatic metabolizing capacity were assessed in all subjects and patients by administration of indocyanine green and antipyrine, respectively. Indocyanine green and antipyrine plasma clearances were decreased by 38 and 51%, respectively, indicating that both functions were diminished by hepatic cirrhosis. We conclude that the moricizine dose required for arrhythmia patients with hepatic disease should be lower, and perhaps, the dosing frequency should be less than in patients with normal liver function.

AB - The pharmacokinetics of moricizine and two of its metabolites, moricizine sulfoxide and phenothiazine-2-carbamic acid ethyl ester sulfoxide, were studied in healthy control subjects and in patients with chronic liver disease (cirrhosis). Moricizine disposition was significantly altered by hepatic cirrhosis. Compared to healthy subjects, the hepatic disease patients had an increased C(max) (59%), an increased t( 1/2 ) (141%), and a reduced plasma clearance (71%). Additionally, small but statistically significant increases were observed for t(max) and the fraction of moricizine not bound to plasma proteins in patients with hepatic disease. The elimination of both moricizine metabolites was also altered by hepatic dysfunction as indicated by significantly prolonged terminal half-lives. Furthermore, there was a reduction in the conversion of moricizine to moricizine sulfoxide. Both hepatic blood flow and hepatic metabolizing capacity were assessed in all subjects and patients by administration of indocyanine green and antipyrine, respectively. Indocyanine green and antipyrine plasma clearances were decreased by 38 and 51%, respectively, indicating that both functions were diminished by hepatic cirrhosis. We conclude that the moricizine dose required for arrhythmia patients with hepatic disease should be lower, and perhaps, the dosing frequency should be less than in patients with normal liver function.

KW - antipyrine

KW - hepatic cirrhosis

KW - indocyanine green

KW - moricizine

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0028299758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028299758&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 243

EP - 252

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

IS - 3

ER -